Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Forte Biosciences, Inc. - Common Stock (NQ: FBRX )

5.820 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.820
Bid (Size) 4.110 (1)
Ask (Size) 9.310 (2)
Prev. Close 5.820
Today's Range 5.820 - 5.820
52wk Range 4.110 - 28.68
Shares Outstanding 21,051,195
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
Why Forte Biosciences (FBRX) Stock Is Trading Lower
Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans for the periodic resale of up to 9.5 million common stock shares by selling stockholders. 
Via Benzinga

Performance

YTD
-76.97%
-76.97%
1 Month
-47.21%
-47.21%
3 Month
-75.71%
-75.71%
6 Month
-18.03%
-18.03%
1 Year
-65.36%
-65.36%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Forte Biosciences to Host R&D Day December 3, 2024
From Forte Biosciences, Inc.
Via Business Wire
FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024
Via InvestorPlace
FBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Forte Biosciences Shares Are Soaring Today: What's Going On?
Via Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results
Via Benzinga
Exposures Fossil Fuels
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views
Via Benzinga
US Stocks Mostly Lower; Target Posts Downbeat Earnings
Via Benzinga
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024
Via InvestorPlace
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Research Frontiers And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Insiders Buying Vintage Wine Estates And 3 Other Stocks Under $1
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.